Edition:
United Kingdom

Newlink genetics announces FDA orphan-drug designation for Indoximod


Monday, 30 Oct 2017 

Oct 30 (Reuters) - Newlink Genetics Corp :Newlink Genetics announces FDA orphan-drug designation for Indoximod.‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​.